[go: up one dir, main page]

WO2025226841A1 - Approche de thérapie génique pour le traitement de troubles associés à tnnt2 - Google Patents

Approche de thérapie génique pour le traitement de troubles associés à tnnt2

Info

Publication number
WO2025226841A1
WO2025226841A1 PCT/US2025/026015 US2025026015W WO2025226841A1 WO 2025226841 A1 WO2025226841 A1 WO 2025226841A1 US 2025026015 W US2025026015 W US 2025026015W WO 2025226841 A1 WO2025226841 A1 WO 2025226841A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
expression
aav
tnnt2
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/026015
Other languages
English (en)
Inventor
Mark Fielden
Mohammadsharif TABEBORDBAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kate Therapeutics Inc
Original Assignee
Kate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kate Therapeutics Inc filed Critical Kate Therapeutics Inc
Publication of WO2025226841A1 publication Critical patent/WO2025226841A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Definitions

  • the invention relates to gene therapy approaches.
  • Cardiomyopathies represents a collection of heart muscle disfunctions and is the second most common cause of heart disease in subjects.
  • cardiomyopathy occurs, the normal muscle in the heart can thicken, stiffen, thin out, or fill with substances the body produces that do not belong in the heart muscle.
  • the heart's ability to pump blood is reduced, which can lead to irregular heartbeats, the backup of blood into the lungs or rest of the body, and heart failure.
  • Cardiac troponin T is a protein in cardiac muscle cells that binds tropomyosin to regulate heart contractions and is encoded by the TNNT2 gene. Mutations in the TNNT2 gene can cause familial hypertrophic cardiomyopathy (HCM), a condition characterized by thickening (hypertrophy) of the cardiac muscle, or dialated cardiomyopathy (DCM), a condition characterized by enlargement and thinning of the left ventricle. TNNT2 gene mutations are found in approximately 5 percent of individuals with this condition, with all affected individuals having an increased risk of heart failure and sudden death. Most TNNT2 gene mutations in familial hypertrophic cardiomyopathy or dialated cardiomyopathy change single amino acids in the cTnT protein. The altered protein is incorporated into the troponin complex, resulting in possible dysfunction.
  • HCM familial hypertrophic cardiomyopathy
  • DCM dialated cardiomyopathy
  • the present invention provides expression cassettes and methods that reduce expression of an endogenous TNNT2 gene while providing a functional TNNT2 transgene (tTNNT2).
  • tTNNT2 TNNT2 transgene
  • aspects of the invention provide an expression cassette comprising a first nucleic acid encoding a TNNT2 transgene (tTNNT2) and a second nucleic acid encoding a sequence that reduces expression of endogenous TNNT2.
  • tTNNT2 transgene TNNT2 transgene
  • tTNNT2 protein incorporation in the sarcomere of the cardiac cell is greater than when the first nucleic acid is expressed alone.
  • tTNNT2 protein incorporation may about double or greater than double the incorporation level when the first nucleic acid is expressed alone.
  • first nucleic acid and/or second nucleic acid may be operably linked to a promoter.
  • the first nucleic acid and/or second nucleic acid may be operably linked to an enhancer.
  • the promoter may comprise a cardiac specific promoter.
  • the promoter may be selected from the group consisting of: TNNT2, Desmin (DES1), and combinations thereof.
  • the expression cassette comprises a vector, for example a viral vector or lipid nanoparticle (LNP).
  • the vector may transport (e.g. encapsidate or encapsulate) the first nucleic and second nucleic acid.
  • the expression cassette may comprise a first vector transporting the first nucleic acid and a second vector transporting the second nucleic acid.
  • the vector may be an adeno-associated viral (AAV) vector, for example an AAV vector modified for increased tropism for cardiac cells.
  • AAV adeno-associated viral
  • the first nucleic acid may encode a codon optimized TNNT2 transgene.
  • the second nucleic acid may encode an RNA interefering (RNAi) molecule which interferes with expression of endogenous TNNT2.
  • RNAi RNA interefering
  • the RNAi molecule maty be a small interfering RNA (siRNA) or micro RNA (miRNA).
  • siRNA small interfering RNA
  • miRNA micro RNA
  • the second nucleic acid may encode an antisense oligonucleotide or ribozyme.
  • the engoenous TNNT2 may be may be a wild-type (e.g. functional) and/or mutant TNNT2.
  • aspects of the invention also provide methods of treating a disorder associated with mutant TNNT2 by providing to a subject an expression cassette of the invention.
  • aspects of the invention provide a method of treating a disorder associated with mutant TNNT2, the method comprising administering to a subject an expression cassette comprising a first nucleic acid encoding a TNNT2 transgene (tTNNT2) and a second nucleic acid encoding a sequence that reduces expression of endogenous TNNT2.
  • tTNNT2 TNNT2 transgene
  • expression of the first nucleic acid and second nucleic acid may result in greater than double the tTNNT2 protein incorporation than from expression of the first nucleic acid is alone.
  • FIG. 1 shows an electrophoresis assay of 3xFLAG-TNNT2 transgene protein levels in mouse heart.
  • FIG. 2 shows a graph of 3xFLAG-TNNT2 transgene expression protein levels in mouse heart.
  • FIG. 3 shows a graph of endogenous mouse Tnnt2 mRNA expression in mouse heart.
  • the present invention provides expression cassettes and methods that reduce expression of an endogenous TNNT2 gene while providing a non-mutant TNNT2 transgene 0TNNT2), resulting in greatly increased TNNT2 transgene incorporation in the sarcomere than from delivery of the TNNT2 transgene alone.
  • Cardiomyopathy is a class of disease of heart muscle that adversely impacts the hearts ability to circulate blood through the cardiovascular system.
  • Various types of cardiomyopathies exist including dilated cardiomyopathy, hypertrophic cardiomyopathy, and restrictive cardiomyopathy. Cardiomyopathy in human populations is a major medical burden and treatment needs are currently unmet, despite cardiomyopathies in human populations being particularly desirable to treat.
  • DCM Dilated cardiomyopathy
  • doxorubicin and daunorubicin are the most common types of human cardiomyopathy, occurring mostly in adults 20 to 60. DCM affects the heart's ventricles and atria, the lower and upper chambers of the heart, respectively. Most forms of DCM are acquired forms from a number of causes that include coronary heart disease, heart attack. high blood pressure, diabetes, thyroid disease, viral hepatitis and viral infections that inflame the heart muscle. Alcohol abuse and certain drugs, such as cocaine and amphetamines, as well as at least two drugs used to treat cancer (doxorubicin and daunorubicin), can also lead to DCM.
  • doxorubicin and daunorubicin can also lead to DCM.
  • DCM DCM associated with Duchenne and Becker muscular dystrophies.
  • the cardiomyopathy can ultimately limit the patient’ s survival.
  • HCM Hypertrophic cardiomyopathy
  • Restrictive cardiomyopathy is a condition leading to a stiffening of the chambers of the heart over time. While the heart’s ability to contract remains largely unaffected, the cardiac muscle does not fully relax between beats of the heart. This restricts the abi 1 i ty of the ventricles to fdl with blood and causes blood to back up in the circulatory system.
  • Heart function is critically dependent upon calcium-dependent signaling. During heart disease, malfunctioning of calcium channels within cardiac cells promotes calcium cycling abnormalities, further inhibiting heart function.
  • HCM hypertrophic cardiomyopathy
  • DCM dilated cardiomyopathy
  • RCM restrictive cardiomyopathy
  • Gene silencing is the regulation of gene expression in a cell to prevent the expression of a certain gene. Gene silencing can occur during either transcription or translation. Gene silencing is used herein interchangeably with gene knockdown and refers to the reduction of expression of a gene.
  • the term “reduced” is used herein to indicate that the target gene expression is lowered by 1-100%. For example, the expression may be reduced by 10, 20, 30, 40. 50. 60, 70, 80, 90, 95, or even 99%.
  • the term “reduced” is used herein to indicate that the target gene expression is lowered by 1-100%. For example, the expression may be reduced by 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or even 99%.
  • antisense oligonucleotides are a gene silencing method in which short nucleic acid fragments bind to complementary target mRNA molecules. These molecules can be composed of single-stranded DNA or RNA and are generally 13-25 nucleotides long.
  • the antisense oligonucleotides can affect gene expression in two ways: by using an RNase IT- dependent mechanism or by using a steric blocking mechanism. RNase H-dependent oligonucleotides cause the target mRNA molecules to be degraded, while steric-blocker oligonucleotides prevent translation of the mRNA molecule.
  • the majority of antisense drugs function through the RNase H-dependent mechanism, in which RNase H hydrolyzes the RNA strand of the DNA/RNA heteroduplex.
  • Ribozymes are catalytic RNA molecules used to inhibit gene expression. Ribozymes work by cleaving mRNA molecules. Several types of ribozyme motifs exist, including hammerhead, hairpin, hepatitis delta virus, group I, group II, and RNase P ribozymes. Hammerhead, hairpin, and hepatitis delta virus (HDV) ribozyme motifs are generally found in viruses or viroid RNAs. These motifs are able to self-cleave a specific phosphodiester bond on an mRNA molecule. Lower eukaryotes and a few bacteria contain group I and group II ribozymes. These motifs can self-splice by cleaving and joining phosphodiester bonds. The RNase P ribozyme, is found in Escherichia coli and is known for its ability to cleave the phosphodiester bonds of several tRNA precursors when joined to a protein cofactor.
  • HDV hepatitis delta
  • the general catalytic mechanism used by ribozy mes is similar to the mechanism used by protein ribonucleases. These catalytic RNA molecules bind to a specific site and attack the neighboring phosphate in the RNA backbone with their 2' oxygen, which acts as a nucleophile, resulting in the formation of cleaved products with a 2'3'-cyclic phosphate and a 5' hydroxyl terminal end. This catalytic mechanism has been increasingly used by scientists to perform sequence-specific cleavage of target mRNA molecules.
  • RNA interference is the process of sequence-specific, post-transcriptional gene silencing initiated by short interference RNA (siRNA). RNAi is seen in a number of organisms such as Drosophila, nematodes, fungi and plants, and is believed to be involved in anti-viral defense, modulation of transposon activity, and regulation of gene expression. During RNAi, RNAi molecules induce degradation of target mRNA with consequent sequence-specific inhibition of gene expression.
  • siRNA short interference RNA
  • a “small interfering” or ‘"short interfering RNA” or siRNA is a RNA duplex of nucleotides that is targeted to a gene interest.
  • a “RNA duplex” refers to the structure formed by the complementary 7 pairing betw een two regions of a RNA molecule.
  • siRNA is "targeted” to a gene in that the nucleotide sequence of the duplex portion of the siRNA is complementary 7 to a nucleotide sequence of the targeted gene.
  • the length of the duplex of siRNAs is less than 30 nucleotides.
  • the duplex can be 29, 28, 27, 26, 25, 24, 23. 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 nucleotides in length.
  • the length of the duplex is 19 - 25 nucleotides in length.
  • the RNA duplex portion of the siRNA can be part of a hairpin structure.
  • the hairpin structure may contain a loop portion positioned between the two sequences that form the duplex.
  • the loop can vary 7 in length. In some embodiments the loop is 5. 6, 7, 8, 9, 10. 11. 12 or 13 nucleotides in length.
  • the hairpin structure can also contain 3' or 5' overhang portions. In some embodiments, the overhang is a 3' or a 5' overhang 0, 1, 2, 3, 4 or 5 nucleotides in length.
  • the “sense” and “antisense” sequences can be used with or without a loop region to form siRNA molecules.
  • siRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi.
  • dsRNA double- stranded RNA
  • miRNA micro-RNA
  • shRNA short hairpin RNA
  • ptgsRNA post- transcriptional gene silencing RNA
  • RNAi is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetic silencing.
  • siRNA molecules of the invention can be used to epigenetically silence genes at both the post-transcriptional level or the prc-transcriptional level.
  • epigenetic modulation of gene expression by siRNA molecules of the invention can result from siRNA mediated modification of chromatin structure or methylation pattern to alter gene expression.
  • modulation of gene expression by siRNA molecules of the invention can result from siRNA mediated cleavage of RNA (either coding or non-coding RNA) via RISC, or alternately, translational inhibition as is known in the art.
  • Embodiments of this disclosure can provide compositions and methods for gene silencing and modulating protein expression using small nucleic acid molecules.
  • nucleic acid molecules include molecules active in RNA interference (RNAi molecules), short interfering RNA (siRNA), double- stranded RNA (dsRNA), micro-RNA (miRNA), or short hairpin RNA (shRNA) molecules, as well as DNA-directed RNAs (ddRNA), Piwi- interacting RNAs (piRNA), or repeat associated siRNAs (rasiRNA).
  • RNAi molecules RNA interference
  • siRNA short interfering RNA
  • dsRNA double- stranded RNA
  • miRNA micro-RNA
  • shRNA short hairpin RNA
  • ddRNA DNA-directed RNAs
  • piRNA Piwi- interacting RNAs
  • rasiRNA repeat associated siRNAs
  • gene silencing can target a specific defective allele.
  • the gene silenced defective allele can then be replaced by a functional copy.
  • the functional copy of a gene is codon optimized, such that dissimilarities between a defective copy and a functional copy allow for silencing only of the defective copy.
  • the siRNA can be encoded by a nucleic acid sequence, and the nucleic acid sequence can also include a promoter.
  • the nucleic acid sequence can also include a polyadenylation signal.
  • the polyadenylation signal is a synthetic minimal polyadenylation signal.
  • the invention may contain a cardiac specific promoter or another promoter.
  • Promoter regions enable the host cells to replicate the AAV delivered nucleic acid only in those cell ty pes and tissues or organs in which the desired protein should be created.
  • the cardiac specific promoter is included because it is principally desired that the proteins only be translated in myocytes. Specificity of the cell type into which the nucleic acid is delivered and thus the proteins translated is desired because of the adverse effects that may ensue from delivering the nucleic acid and having it translated in cells in which that nucleic acid and thus protein is not needed.
  • the promoter comprises a cardiac specific promoter. In some embodiments, the promoter is TNNT2. In some embodiments, the promoter is MHCK9. In some embodiments, the promoter is MHCK7. In some embodiments, the promoter is CB A (Chicken -Actin). In some embodiments, the promoter is CMV or mini CMV. In some embodiments, the promoter is a Desmin promoter.
  • the promoters described herein are inserted into an AAV protein (e.g., an AAV capsid protein) that has reduced specificity (or no detectable, measurable, or clinically relevant interaction) for one or more non-muscle cell ty pes.
  • AAV protein e.g., an AAV capsid protein
  • Exemplary non-muscle cell types include, but are not limited to, liver, kidney, lung, spleen, central or peripheral nervous system cells, bone, immune, stomach, intestine, eye, skin cells and the like.
  • the non-muscle cells are liver cells.
  • operably linked refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other.
  • Gene therapy utilizes the delivery of DNA or RNA into cells through a delivery' system, referred to as a vector.
  • a delivery' system referred to as a vector.
  • Non-viral vectors depend on physical or chemical methods of delivering genetic material into a cell. This can be either a physical technique or a chemical technique. Physical methods allow researchers to directly deliver genetic material to target cells (for example, using an injection needle). Chemical methods use natural or synthetic materials, for example fat molecules (lipids), polymers, and nanoparticles, or a comination thereof.
  • lipids fat molecules
  • polymers polymers
  • nanoparticles or a comination thereof.
  • electroporation is a non-viral delivery method being studied to deliver gene therapy in clinical trials.
  • electroporation scientists use pulses of electricity' to cause temporary pores to form in a cell membrane. These pores enable gene therapy to be delivered into the cell where it can take effect.
  • Other techniques include the use of a ‘"gene gun,” which uses force), sonoporation (which uses sound), and photoporation (which uses light) to deliver genetic material into a cell.
  • LNPs lipid nanoparticles
  • LNPs encapsulate and protect genetic material from degradation before it can reach target cells.
  • LNPs provide the advantage of being quick to manufacture, efficient, and scalable to the size of the material being delivered.
  • Viral vectors are built using engineered viral capsids that encapsidate DNA or RNA for delivery’.
  • the most common viral vectors are lentiviral vectors (LVVs) and adenoviral vectors (AAVs).
  • LVVs are a species of retrovirus.
  • Lentiviral vectors have the ability to enter the cell and insert its genetic material into dividing cells (such as stem cells) and non-dividing cells (such as cardiac cells). Lentiviruses also integrate genetic material into the host genome, which alloyvs for continued gene expression.
  • AAVs are particularly appropriate viral vectors for delivery of genetic material into mammalian cells.
  • AAVs are not known to cause disease in mammals and cause a very mild immune response. Additionally, AAVs are able to infect cells in multiple stages whether at rest or in a phase of the cell replication cycle.
  • AAV DNA is not regularly inserted into the host’s genome at random sites, reducing the oncogenic properties of this vector.
  • AAVs have been engineered to deliver a variety of treatments, especially for genetic disorders caused by single nucleotide polymorphisms (“SNP”). Genetic diseases that have been studied in conjunction with AAV vectors include Cystic fibrosis, hemophilia, arthritis, macular degeneration, muscular dystrophy, Parkinson’s disease, congestive heart failure, and Alzheimer's disease.
  • SNP single nucleotide polymorphisms
  • the AAV can be used as a vector to deliver engineered nucleic acid to a host and utilize the host’s own ribosomes to transcribe that nucleic acid into the desired proteins. See, e.g.. West et al.. Virology 160:38-47 (1987); U.S. Pat. No.
  • AAVs have some deficiency in their replication and/or pathogenicity and thus can be safer that adenoviral vectors.
  • the AAV can integrate into a specific site on chromosome 19 of a human cell with no observable side effects.
  • the capacity of the AAV vector, system thereof, and/or AAV particles can be up to about 4.7 kb.
  • the AAV vector or system thereof can include one or more engineered capsid polynucleotides described herein.
  • AAV s are small, replication-defective, nonenveloped viruses that infect humans and other primate species and have a linear single-stranded DNA genome.
  • Naturally occurring AAV seroty pes exhibit liver tropism.
  • transfection of non-liver tissue with traditional AAV vectors is impeded by’ the virus's natural liver tropism.
  • the liver acts to break down substances delivered to a subject
  • transfection of non-liver tissue with unmodified AAV vectors requires higher dosing to provide sufficient viral load to overcome the liver and reach non-liver tissue. More than 30 naturally occurring serotypes of AAV are available. Many natural variants in the AAV capsid exist.
  • AAV serotypes include, but are not limited to, AAV serotypes AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV 12, AAV13.
  • AAVs may be engineered using conventional molecular biology techniques, making it possible to optimize these particles, for example, for cell specific delivery, for minimizing immunogenicity, for tuning stability and particle lifetime, for efficient degradation, for accurate delivers’ to the nucleus.
  • AAV vectors can be specifically targeted to one or more types of cells by choosing the appropriate combination of AAV serotype, promoter, and delivery’ method.
  • mapping determinants of AAV tropism have been carried out by comparing highly related seroty pes.
  • One such example is the singleamino acid change (E531K) between AAV1 and AAV6 that improves murine liver transduction in AAV1. See Wu et al. (2006) J. Virol.. 80(22): 11393-7, incorporated by reference herein.
  • AAVs exhibiting modified tissue tropism that may be used with the present invention are described in U.S. Patent No. 9,695,220, U.S. Patent No. 9,719,070; U.S. Patent No. 10,119,125; U.S. Patent No. 10,526,584; U.S. Patent Application Publication No. 2018- 0369414; U.S. Patent Application Publication No. 2020-0123504; U.S. Patent Application Publication No. 2020-0318082; PCT International Patent Application Publication No. WO 2015/054653; PCT International Patent Application Publication No. WO 2016/179496; PCT International Patent Application Publication No. WO 2017/100791; and PCT International Patent Application Publication No. WO 2019/217911, the entirety of the contents of each of which are incorporated by reference herein.
  • the AAV vector or system thereof may include one or more regulatory molecules, such as promoters, enhancers, repressors and the like.
  • the AAV vector or system thereof can include one or more polynucleotides that can encode one or more regulatory proteins.
  • the one or more regulatory proteins can be selected from Rep78, Rep68, Rep52, Rep40, variants thereof, and combinations thereof.
  • the muscle specific promoter can drive expression of an engineered AAV capsid polynucleotide.
  • the AAV vector or system thereof can include one or more polynucleotides that can encode one or more capsid proteins, such as the engineered AAV capsid proteins described elsewhere herein.
  • the engineered capsid proteins can be capable of assembling into a protein shell (an engineered capsid) of the AAV virus particle.
  • the engineered capsid can have a cell-, tissue-, and/or organ-specific tropism.
  • the AAV vector or system thereof can be configured to produce AAV particles having a specific serotype.
  • the serotype can be AAV-1, AAV -2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9 or any combinations thereof.
  • the AAV can be AAV1, AAV-2, AAV-5, AAV-9 or any combination thereof.
  • an AAV vector or system thereof capable of producing AAV particles capable of targeting the brain and/or neuronal cells can be configured to generate AAV particles having serotypes 1, 2, 5 or a hybrid capsid AAV-1, AAV-2, AAV-5 or any combination thereof.
  • an AAV vector or system thereof capable of producing AAV particles capable of targeting cardiac tissue can be configured to generate an AAV particle having an AAV -4 serotype.
  • an AAV vector or system thereof capable of producing AAV particles capable of targeting the liver can be configured to generate an AAV having an AAV-8 serotype. See also Srivastava. 2017. Curr. Opin. Virol. 21 :75-80.
  • each serotype still is multi-tropic and thus can result in tissuetoxicity if using that seroty pe to target a tissue that the serotype is less efficient in transducing.
  • the tropism of the AAV serotype can be modified by an engineered AAV capsid described herein.
  • variants of wild-type AAV of any seroty pe can be generated via a method described herein and determined to have a particular cell-specific tropism, which can be the same or different as that of the reference wild-type AAV serotype.
  • the cell, tissue, and/or specificity of the wild-type serotype can be enhanced (e.g., made more selective or specific for a particular cell type that the serotype is already biased towards).
  • wild- type AAV-9 is biased towards muscle and brain in humans (see e.g., Srivastava. 2017. Curr. Opin. Virol. 21 :75-80.)
  • the tropism for nervous cells might be reduced or eliminated and/or the muscle specificity increased such that the nervous specificity appears reduced in comparison, thus enhancing the specificity for muscle as compared to the wild-type AAV-9.
  • an engineered capsid and/or capsid protein variant of a wild-type AAV serotype can have a different tropism than the wild-type reference AAV serotype.
  • an engineered AAV capsid and/or capsid protein variant of AAV-9 can have specificity’ for a tissue other than muscle or brain in humans.
  • the AAV vector is a hybrid AAV vector or system thereof.
  • Hybrid AAVs are AAVs that include genomes with elements from one serotype that are packaged into a capsid derived from at least one different serotype. For example, if it is the rAAV2/5 that is to be produced, and if the production method is based on the helper-free, transient transfection method discussed above, the 1st plasmid and the 3rd plasmid (the adeno helper plasmid) will be the same as discussed for rAAV2 production. However, the 2nd plasmid, the pRepCap will be different.
  • pRep2/Cap5 the Rep gene is still derived from AAV2, while the Cap gene is derived from AAV5.
  • the production scheme is the same as the above-mentioned approach for AAV2 production.
  • the resulting rAAV is called rAAV2/5, in which the genome is based on recombinant AAV2, while the capsid is based on AAV5. It is assumed the cell or tissue-tropism displayed by this AAV2/5 hybrid virus should be the same as that of AAV5. It will be appreciated that wild-type hybrid AAV particles suffer the same specificity issues as with the non-hybrid wild-type seroty pes previously discussed.
  • hybrid AAVs can contain an engineered AAV capsid containing a genome with elements from a different serotype than the reference wild-type serotype that the engineered AAV capsid is a variant of.
  • a hybrid AAV can be produced that includes an engineered AAV capsid that is a variant of an AAV-9 seroty pe that is used to package a genome that contains components (e.g., rep elements) from an AAV -2 serotype.
  • the tropism of the resulting AAV particle will be that of the engineered AAV capsid.
  • the AAV vector or system thereof is configured as a “gutless” vector, similar to that described in connection with a retroviral vector.
  • the “gutless” AAV vector or system thereof can have the cis-acting viral DNA elements involved in genome amplification and packaging in linkage with the heterologous sequences of interest (e.g., the engineered AAV capsid polynucleotide(s)).
  • the vectors described herein can be constructed using any suitable process or technique.
  • one or more suitable recombination and/or cloning methods or techniques can be used to the vector(s) described herein.
  • Suitable recombination and/or cloning techniques and/or methods can include, but not limited to, those described in U.S. Application publication No. US 2004-0171156 Al. Other suitable methods and techniques are described elsewhere herein.
  • AAV vectors Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81 :6466-6470 (1984); and Samulski et al.. J. Virol. 63:03822-3828 (1989). Any of the techniques and/or methods can be used and/or adapted for constructing an AAV or other vector described herein. AAV vectors are discussed elsew here herein.
  • the vector can have one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a “cloning site’ ? ).
  • one or more insertion sites e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
  • Delivery vehicles, vectors, particles, nanoparticles, formulations and components thereof for expression of one or more elements of a engineered AAV capsid system described herein are as used in the foregoing documents, such as International Patent Application Publications WO WO 2021/050974 and WO 2021/077000 and PCT International Application No. PCT/US2021/042812, the contents of which are incorporated by reference herein.
  • AAV vectors are described in International Patent Application Publications WO 2005/033321; WO 2006/110689; WO 2007/127264; WO 2008/027084; WO 2009/073103; WO 2009/073104; WO 2009/105084; WO 2009/134681; WO 2009/136977; WO 2010/051367; WO 2010/138675; WO 2001/038187; WO 2012/112832; WO 2015/054653; WO 2016/179496; WO 2017/100791; WO 2017/019994; WO 2018/209154; WO 2019/067982; WO 2019/195701 ; WO 2019/21791 1 ; WO 2020/041498; WO 2020/210839; U.S.
  • the capsid protein is the shell or coating of the virus that enables its delivery into the host. Without the protein, the nucleic acids would be destroyed by the host without entering into the host cells and beginning transcription and translation.
  • the capsid protein may be in the natural conformation of a naturally occurring AAV, or it may be modified.
  • the AAV capsid protein is an engineered AAV capsid protein having reduced or eliminated uptake in a non-muscle cell as compared to a corresponding wild-type AAV capsid polypeptide.
  • the engineered AAV capsid encoding polynucleotide can be included in a polynucleotide that is configured to be an AAV genome donor in an AAV vector system that can be used to generate engineered AAV particles described elsewhere herein.
  • the engineered AAV capsid encoding polynucleotide can be operably coupled to a poly adenylation tail.
  • the poly adenylation tail can be an SV40 poly adenylation tail.
  • the AAV capsid encoding polynucleotide can be operably coupled to a promoter.
  • the promoter can be a tissue specific promoter.
  • the tissue specific promoter is specific for muscle (e.g.. cardiac muscle), neurons and supporting cells (e.g.. astrocytes, glial cells, Schwann cells, etc ), fat, spleen, liver, kidney, immune cells, spinal fluid cells, synovial fluid cells, skin cells, cartilage, tendons, connective tissue, bone, pancreas, adrenal gland, blood cell, bone marrow cells, placenta, endothelial cells, and combinations thereof.
  • the promoter can be a constitutive promoter. Suitable tissue specific promoters and constitutive promoters are discussed elsewhere herein and are generally known in the art and can be commercially available.
  • Suitable muscle specific promoters include, but are not limited to CK8, MHCK7, Myoglobin promoter (Mb), Desmin promoter, muscle creatine kinase promoter (MCK) and variants thereof, and SPc5-12 synthetic promoter.
  • engineered viral capsids such as adeno-associated virus (AAV) capsids
  • AAV adeno-associated virus
  • Engineered viral capsids can be lentiviral, retroviral, adenoviral, or AAV capsids.
  • the engineered capsids can be included in an engineered virus particle (e g., an engineered lentiviral, retroviral, adenoviral, or AAV virus particle), and can confer cell-specific tropism, reduced immunogenicity, or both to the engineered viral particle.
  • the engineered viral capsids described herein can include one or more engineered viral capsid proteins described herein.
  • the engineered viral capsids described herein can include one or more engineered viral capsid proteins described herein that can contain a muscle-specific targeting moiety containing or composed of an n-mer motif described elsewhere herein.
  • the engineered viral capsid and/or capsid proteins can be encoded by one or more engineered viral capsid polynucleotides.
  • the engineered viral capsid polynucleotide is an engineered AAV capsid polynucleotide, engineered lentiviral capsid polynucleotide, engineered retroviral capsid polynucleotide, or engineered adenovirus capsid polynucleotide.
  • an engineered viral capsid polynucleotide e.g...
  • an engineered AAV capsid polynucleotide, engineered lentiviral capsid polynucleotide, engineered retroviral capsid polynucleotide, or engineered adenovirus capsid polynucleotide) can include a 3’ polyadenylation signal.
  • the polyadenylation signal can be an SV40 polyadenylation signal.
  • the engineered viral capsids can be variants of wild-type viral capsid.
  • the engineered AAV capsids can be variants of wild-ty pe AAV capsids.
  • the wild-type AAV capsids can be composed of VP1, VP2, VP3 capsid proteins or a combination thereof.
  • the engineered AAV capsids can include one or more variants of a wild-type VP1, wild-type VP2, and/or wild-type VP3 capsid proteins.
  • the serotype of the reference wild-type AAV capsid can be AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9 or any combination thereof.
  • the serotype of the wild-ty pe AAV capsid can be AAV-9.
  • the engineered AAV capsids can have a different tropism than that of the reference wild-type AAV capsid.
  • the engineered viral capsid can contain 1-60 engineered capsid proteins. In some embodiments, the engineered viral capsids can contain 1, 2. 3, 4, 5, 6, 7, 8, 9. 10. 11.
  • the engineered viral capsid can contain 0- 59 wild-type viral capsid proteins. In some embodiments, the engineered viral capsid can contain 0, 1, 2. 3, 4, 5, 6. 7, 8, 9. 10. 11. 12. 13, 14, 15, 16, 17, 18, 19, 20, 21, 22. 23. 24. 25.
  • the engineered AAV capsid can contain 1 -60 engineered capsid proteins. In some embodiments, the engineered AAV capsids can contain 1. 2, 3, 4. 5,
  • the engineered AAV capsid can contain 0-59 wild-type AAV capsid proteins.
  • the engineered AAV capsid can contain 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59 wild-ty pe AAV capsid proteins.
  • the engineered viral capsid protein can have an n-mer amino acid motif, where n can be at least 3 amino acids. In some embodiments, n can be 3, 4, 5, 6,
  • an engineered AAV capsid can have a 6-mer or 7-mer amino acid motif.
  • the n-mer amino acid motif can be inserted between two amino acids in the wild-type viral protein (VP) (or capsid protein).
  • the n-mer motif can be inserted between two amino acids in a variable amino acid region in a viral capsid protein.
  • the n-mer motif can be inserted between two amino acids in a variable amino acid region in an AAV capsid protein.
  • the core of each wild-type AAV viral protein contains an eight-stranded beta-barrel motif (betaB to betal) and an alpha-helix (alphaA) that are conserved in autonomous parvovirus capsids (see e.g., DiMattia et al. 2012. J. Virol. 86(12):6947-6958).
  • Structural variable regions (VRs) occur in the surface loops that connect the beta-strands, which cluster to produce local variations in the capsid surface.
  • AAVs have 12 variable regions (also referred to as hypervariable regions) (see e.g., Weitzman and Linden. 2011. “Adeno- Associated Virus Biology.” In Snyder, R.O., Moullier, P. (eds.) Totowa. NJ: Humana Press).
  • one or more /7-mer motifs can be inserted between two amino acids in one or more of the 12 variable regions in the w ildtype AVV capsid proteins.
  • the one or more /7-mer motifs can be each be inserted between two amino acids in VR-I, VR-II, VR-III, VR-IV, VR-V, VR-VI, VR-VII, VR-III, VR-IX, VR-X, VR-XI, VR-XII, or a combination thereof.
  • the /7-mer can be inserted between two amino acids in the VR-III of a capsid protein.
  • the engineered capsid can have an n-mer inserted between any two contiguous amino acids between amino acids 262 and 269, between any two contiguous amino acids between amino acids 327 and 332, between any tw o contiguous amino acids between amino acids 382 and 386, between any two contiguous amino acids between amino acids 452 and 460, between any two contiguous amino acids between amino acids 488 and 505, between any two contiguous amino acids between amino acids 545 and 558, between any two contiguous amino acids between amino acids 581 and 593, between any two contiguous amino acids betw een amino acids 704 and 714 of an AAV9 viral protein.
  • the engineered capsid can have an /7-mer inserted between amino acids 588 and 589 of an AAV9 viral protein.
  • the engineered capsid can have a 7- mer motif inserted between amino acids 588 and 589 of an AAV9 viral protein.
  • the motif inserted is a 10-mer motif, with replacement of amino acids 586-88 and an insertion before 589.
  • /7-mers can be inserted in analogous positions in AAV viral proteins of other serotypes.
  • the n-mer(s) can be inserted between any two contiguous amino acids within the AAV viral protein and in some embodiments the insertion is made in a variable region.
  • the first 1, 2, 3, or 4 amino acids of an n-mer motif can replace 1, 2, 3, or 4 amino acids of a polypeptide into which it is inserted and preceding the insertion site.
  • the amino acids of the n-mer motif that replace 1 or more amino acids of the polypeptide into which the n-mer motif is inserted come before or immediately before an “RGD”’ in an n-mer motif, referred to as a MyoAAV capsid.
  • one or more of the n-mer motifs can be inserted into e.g., and AAV9 capsid prolylpeptide between amino acids 588 and 589 and the insert can replace amino acids 586, 587, and 588 such that the amino acid immediately preceding the n-mer motif after insertion is residue 585.
  • this principle can apply in any other insertion context and is not necessarily limited to insertion betw een residues 588 and 589 of an AAV9 capsid or equivalent position in another AAV capsid.
  • no amino acids in the polypeptide into which the n- mer motif is inserted are replaced by the n-mer motif.
  • the AAV capsids or other viral capsids or compositions can be cardiac-specific.
  • cardiac-specificity of the engineered AAV or other viral capsid or other composition is conferred by a muscle specific n-mer motif incorporated in the engineered AAV or other viral capsid or other composition described herein. While not intending to be bound by theory, it is believed that the n-mer motif confers a 3D structure to or within a domain or region of the engineered AAV capsid or other viral capsid or other composition such that the interaction of the viral particle or other composition containing the engineered AAV capsid or other viral capsid or other composition described herein has increased or improved interactions (e.g..
  • the cell surface receptor is AAV receptor (AAVR).
  • the cell surface receptor is a muscle cell specific AAV receptor.
  • the cell surface receptor or other molecule is a cell surface receptor or other molecule selectively expressed on the surface of a muscle cell.
  • the cell surface receptor or molecule is an integrin or dimer thereof.
  • the cell surface receptor or molecule is an Vb6 integrin heterodimer.
  • a muscle specific engineered viral particle or other composition described herein containing the muscle-specific capsid, n-mer motif, or musclespecific targeting moiety described herein can have an increased uptake, delivery rate, transduction rate, efficiency, amount, or a combination thereof in a muscle cell as compared to other cells types and/or other virus particles (including but not limited to AAVs) and other compositions that do not contain the muscle-specific n-mer motif of the present invention.
  • First-and second-generation muscle specific AAV capsids were developed using a muscle specific promoter and the resulting capsid libraries were screened in mice and nonhuman primates as described elsewhere herein and/or in e.g. WO 2021/050974 and WO 2021/077000.
  • First and second generation myoAAV capsids were further optimized in mice and non-human primates as previously described to generate enhanced myoAAV capsids.
  • compositions e.g., rAAV particle, AAV vector, pharmaceutical composition
  • the composition is a rAAV capsid protein described herein.
  • the composition is an isolated and purified rAAV capsid protein described herein.
  • the rAAV particle encapsidates an AAV vector comprising a transgene (e.g., therapeutic nucleic acid).
  • the composition is a rAAV capsid protein described herein conjugated with a therapeutic agent disclosed herein.
  • the composition is a pharmaceutical composition comprising the rAAV particle and a pharmaceutically acceptable carrier.
  • the one or more compositions are administered to the subject alone (e.g., stand-alone therapy).
  • the composition is a first-line therapy for the disease or condition.
  • the composition is a second-line, third-line, or fourth-line therapy, for the disease or condition.
  • Recombinant adeno-associated virus (rAAV) mediated gene delivery leverages the AAV mechanism of viral transduction for nuclear expression of an episomal heterologous nucleic acid (e.g., a transgene, therapeutic nucleic acid).
  • an episomal heterologous nucleic acid e.g., a transgene, therapeutic nucleic acid.
  • a rAAV Upon delivery to a host in vivo environment, a rAAV will (1) bind or attach to cellular surface receptors on the target cell.
  • rAAVs engineered to have an increased transduction enrichment transcription of the episomal heterologous nucleic acid in the host cell are desirable for gene therapy applications.
  • aspects disclosed herein provide methods of treating a disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of the rAAV of the present disclosure, or the pharmaceutical formulation of the present disclosure, wherein the gene product is a therapeutic gene product.
  • the administering is by intracranial, intraventricular, intracerebroventricular, intravenous, intraarterial, intranasal, intrathecal, intracistemal, or subcutaneous.
  • a disease or a condition associated with an aberrant expression or activity of a target gene or gene expression product thereof comprising modulating the expression or the activity of a target gene or gene expression product in a subject by administering a rAAV encapsidating a heterologous nucleic acid of the present disclosure.
  • the expression or the activity of the target gene or gene expression product is decreased, relative to that in a normal (non- diseased) individual; and administering the rAAV to the subject is sufficient to increase the expression of the activity’ of the target gene or gene expression product.
  • the expression or the activity 7 of the gene or gene expression product is increased, relative to that in a normal individual; and administering the rAAV to the subject is sufficient to decrease the expression or the activity of the target gene or gene expression product.
  • Also provided are methods of preventing a disease or condition disclosed herein in a subject comprising administering to the subject a therapeutically effective amount of an rAAV vector comprising a nucleic acid sequence encoding a therapeutic gene expression product described herein.
  • the rAAV vector may be encapsidated in the modified capsid protein or rAAV viral particle described herein.
  • the therapeutic gene expression product is effective to modulate the activity or expression of a target gene or gene expression product.
  • compositions of the present disclosure are particularly useful for the treatment of the diseases or conditions described herein because they specifically or more efficiently target the in vivo environment and deliver a therapeutic nucleic acid engineered to modulate the activity or the expression of a target gene expression product involved with the pathogenesis or pathology of the disease or condition.
  • a disease or a condition, or a symptom of the disease or condition in a subject, comprising: (a) diagnosing a subject with a disease or a condition affecting a target in vivo environment; and (b) treating the disease or the condition by administering to the subject a therapeutically 7 effective amount of a composition disclosed herein (e.g., rAAV particle, AAV vector, pharmaceutical composition), wherein the composition is engineered with an increased specificity for the target in vivo environment.
  • a composition disclosed herein e.g., rAAV particle, AAV vector, pharmaceutical composition
  • Disclosed herein are methods of treating a disease or a condition, or a symptom of the disease or the condition, afflicting a target in a subject comprising: (a) administering to the subject a composition (e.g., rAAV particle, AAV vector, pharmaceutical composition); and (b) expressing the therapeutic nucleic acid into a target in vivo environment in the subject with an increased transduction enrichment.
  • a composition e.g., rAAV particle, AAV vector, pharmaceutical composition
  • compositions comprising administering to a subject in need thereof a composition (e.g., rAAV particle, AAV vector, pharmaceutical composition) disclosed herein.
  • methods provided herein comprise administering to a subject a rAAV with a rAAV capsid protein encapsidating a viral vector comprising a heterologous nucleic acid that modulates the expression or the activity 7 of the target gene expression product.
  • Some embodiments of the invention may include any acceptable form of providing the AAV vector to a subject.
  • the AAV vector may be provided to the subject in the form of a composition or formulation comprising the AAV vector.
  • the expression vector of this invention can be formulated and administered to treat a variety of disease states by any means that produces contact of the active ingredient with the agent's site of action in the body of the subject.
  • the compositions, polynucleotides, polypeptides, particles, cells, vector systems and combinations thereof described herein can be contained in a formulation, such as a pharmaceutical formulation.
  • the formulations can be used to generate polypeptides and other particles that include one or more muscle-specific targeting moieties described herein.
  • the formulations can be delivered to a subject in need thereof.
  • component(s) of the engineered AAV capsid system, engineered cells, engineered AAV capsid particles, and/or combinations thereof described herein can be included in a formulation that can be delivered to a subject or a cell.
  • the formulation is a pharmaceutical formulation.
  • One or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be provided to a subject in need thereof or a cell alone or as an active ingredient, such as in a pharmaceutical formulation.
  • compositions containing an amount of one or more of the polypeptides, polynucleotides, vectors, cells, or combinations thereof described herein.
  • the pharmaceutical formulation can contain an effective amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein.
  • the pharmaceutical formulations described herein can be administered to a subject in need thereof or a cell.
  • the amount of the one or more of the polypeptides, polynucleotides, vectors, cells, virus particles, nanoparticles, other delivery' particles, and combinations thereof described herein contained in the pharmaceutical formulation can range from about 1 pg/kg to about 10 mg/kg based upon the body weight of the subject in need thereof or average body weight of the specific patient population to which the pharmaceutical formulation can be administered.
  • the amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein in the pharmaceutical formulation can range from about 1 pg to about 10 g, from about 10 nL to about 10 ml.
  • the amount can range from about 1 cell to 1 x 10 2 , I x IO 3 , I x 10 4 , 1 x 10 5 , I x 10 6 , 1 x 10 7 , 1 x IO 8 , 1 x 10 9 , 1 x IO 10 or more cells.
  • the amount can range from about 1 cell to 1 x 10 2 , 1 x 10 3 , 1 x 10 4 , 1 x 10 5 , 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x IO 10 or more cells per nL, pL, mL, or L.
  • the formulation can contain 1 to 1 x 10 2 , 1 x 10 3 . 1 x 10 4 , 1 x 10 5 , 1 x 10 6 . 1 x 10 7 , 1 x 10 8 , 1 x 10 9 . 1 x IO 10 , 1 x 10 11 , 1 x 10 12 . 1 x 10 13 . 1 x 10 14 , 1 x 10 15 , 1 x 10 16 . 1 x 10 17 , 1 x 10 18 , 1 x 10 19 , or 1 x IO 20 transducing units (TU)/mL of the engineered AAV capsid particles.
  • the formulation can be 0.
  • 1 to 100 mL in volume can contain 1 to 1 x 10 2 , 1 x 10 3 , 1 x 10 4 , 1 x 10 5 , 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x IO 10 , 1 x 10 11 , 1 x 10 12 , 1 x 10 13 , 1 x 10 14 . 1 x 10 15 , 1 x 10 16 , 1 x 10 17 . 1 x 10 18 , 1 x 10 19 , or 1 x IO 20 transducing units (TU)/mL of the engineered AAV capsid particles.
  • TU transducing units
  • the pharmaceutical formulation containing an amount of one or more of the polypeptides, polynucleotides, vectors, cells, virus particles, nanoparticles, other delivery particles, and combinations thereof described herein can further include a pharmaceutically acceptable carrier.
  • suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxy methylcellulose, and polyvinyl pyrrolidone, which do not deleteriously react with the active composition.
  • the pharmaceutical formulations can be sterilized, and if desired, mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances, and the like which do not deleteriously react with the active composition.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances, and the like which do not deleteriously react with the active composition.
  • the pharmaceutical formulations described herein may be in a dosage form.
  • the dosage forms can be adapted for administration by any appropriate route.
  • Appropriate routes include, but are not limited to, oral (including buccal or sublingual), rectal, epidural, intracranial, intraocular, inhaled, intranasal, topical (including buccal, sublingual, or transdermal), vaginal, intraurethral, parenteral, intracranial, subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal, intraosseous, intracardiac, intraarticular, intracavemous, intrathecal, intravitreaL intracerebral, gingival, subgingival, intracerebroventricular, and intradermal.
  • Such formulations may be prepared by any method known in the art.
  • Dosage forms adapted for oral administration can be discrete dosage units such as capsules, pellets or tablets, powders or granules, solutions, or suspensions in aqueous or nonaqueous liquids; edible foams or whips, or in oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the pharmaceutical formulations adapted for oral administration also include one or more agents which flavor, preserve, color, or help disperse the pharmaceutical formulation.
  • Dosage forms prepared for oral administration can also be in the form of a liquid solution that can be delivered as foam, spray, or liquid solution.
  • the oral dosage form can contain about 1 ng to 1000 g of a pharmaceutical formulation containing a therapeutically effective amount or an appropriate fraction thereof of the targeted effector fusion protein and/or complex thereof or composition containing the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein.
  • the oral dosage form can be administered to a subject in need thereof.
  • the dosage forms described herein can be microencapsulated.
  • the dosage form can also be prepared to prolong or sustain the release of any ingredient.
  • the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be the ingredient whose release is delayed.
  • the release of an optionally included auxiliary ingredient is delayed.
  • Suitable methods for delaying the release of an ingredient include, but are not limited to, coating or embedding the ingredients in material in polymers, wax, gels, and the like. Delayed release dosage formulations can be prepared as described in standard references such as "Pharmaceutical dosage form tablets," eds. Liberman et. al. (New York, Marcel Dekker, Inc..
  • suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name EUDRAGIT (Roth Pharma, Westerstadt, Germany), zein, shellac, and polysaccharides.
  • cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate
  • polyvinyl acetate phthalate acrylic acid polymers and copolymers
  • methacrylic resins that are commercially available under the trade name EUDRAGIT (Roth Pharma, Westerstadt, Germany), ze
  • Coatings may be formed with a different ratio of water-soluble polymer, water insoluble polymers, and/or pH dependent polymers, with or without water insoluble/water soluble non-polymeric excipient, to produce the desired release profile.
  • the coating is either performed on the dosage form (matrix or simple) which includes, but is not limited to, tablets (compressed with or without coated beads), capsules (with or without coated beads), beads, particle compositions, "ingredient as is” formulated as, but not limited to, suspension form or as a sprinkle dosage form.
  • Dosage forms adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.
  • the pharmaceutical formulations are applied as a topical ointment or cream.
  • the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein can be formulated with a paraffinic or water- miscible ointment base.
  • the active ingredient can be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • Dosage forms adapted for topical administration in the mouth include lozenges, pastilles, and mouth washes.
  • Dosage forms adapted for nasal or inhalation administration include aerosols, solutions, suspension drops, gels, or dry powders.
  • the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein is contained in a dosage form adapted for inhalation is in a particle-size-reduced form that is obtained or obtainable by micronization.
  • the particle size of the size reduced (e.g., micronized) compound or salt or solvate thereof is defined by a D50 value of about 0.5 to about 10 microns as measured by an appropriate method known in the art.
  • Dosage forms adapted for administration by inhalation also include particle dusts or mists.
  • Suitable dosage forms wherein the carrier or excipient is a liquid for administration as a nasal spray or drops include aqueous or oil solutions/suspensions of an active ingredient (e.g., the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein and/or auxiliary active agent), which may be generated by various types of metered dose pressurized aerosols, nebulizers, or insufflators.
  • an active ingredient e.g., the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein and/or auxiliary active agent
  • the dosage forms can be aerosol formulations suitable for administration by inhalation.
  • the aerosol formulation can contain a solution or fine suspension of the one or more of the polypeptides, polynucleotides. vectors, cells, and combinations thereof described herein and a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container.
  • the sealed container is a single dose or multi-dose nasal, or an aerosol dispenser fitted with a metering valve (e.g., metered dose inhaler), which is intended for disposal once the contents of the container have been exhausted.
  • the dispenser contains a suitable propellant under pressure, such as compressed air, carbon dioxide, or an organic propellant, including but not limited to a hydrofluorocarbon.
  • a suitable propellant under pressure such as compressed air, carbon dioxide, or an organic propellant, including but not limited to a hydrofluorocarbon.
  • the aerosol formulation dosage forms in other embodiments are contained in a pump-atomizer.
  • the pressurized aerosol formulation can also contain a solution or a suspension of one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein.
  • the aerosol formulation can also contain co-solvents and/or modifiers incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation.
  • Administration of the aerosol formulation can be once daily or several times daily, for example 2, 3, 4, or 8 times daily, in which 1 , 2, or 3 doses are delivered each time.
  • the pharmaceutical formulation is a dry powder inhalable formulation.
  • an auxiliary active ingredient, and/or pharmaceutically acceptable salt thereof such a dosage form can contain a powder base such as lactose, glucose, trehalose, mannitol, and/or starch.
  • the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein is in a particle-size reduced form.
  • a performance modifier such as L-leucine or another amino acid, cellobiose octaacetate, and/or metals salts of stearic acid, such as magnesium or calcium stearate.
  • the aerosol dosage forms can be arranged so that each metered dose of aerosol contains a predetermined amount of an active ingredient, such as the one or more of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein.
  • Dosage forms adapted for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.
  • Dosage forms adapted for rectal administration include suppositories or enemas.
  • Dosage forms adapted for parenteral administration and/or adapted for any type of injection e.g.
  • intravenous, intraperitoneal, subcutaneous, intramuscular, intradermal, intraosseous, epidural, intracardiac, intraarticular, intracavemous, gingival, subgingival, intrathecal, intravitreal, intracerebral, and intracerebroventricular) can include aqueous and/or non-aqueous sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, solutes that render the composition isotonic with the blood of the subject, and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.
  • the dosage forms adapted for parenteral administration can be presented in a single- unit dose or multi-unit dose containers, including but not limited to sealed ampoules or vials.
  • the doses can be lyophilized and resuspended in a sterile carrier to reconstitute the dose prior to administration.
  • Extemporaneous injection solutions and suspensions can be prepared in some embodiments, from sterile powders, granules, and tablets.
  • Dosage forms adapted for ocular administration can include aqueous and/or nonaqueous sterile solutions that can optionally be adapted for injection, and which can optionally contain anti-oxidants, buffers, bacteriostats, solutes that render the composition isotonic with the eye or fluid contained therein or around the eye of the subject, and aqueous and nonaqueous sterile suspensions, which can include suspending agents and thickening agents.
  • the dosage form contains a predetermined amount of the one or more of the polypeptides, polynucleotides, vectors, cells, and combinations thereof described herein per unit dose.
  • the predetermined amount of the Such unit doses may therefore be administered once or more than once a day.
  • Such pharmaceutical formulations may be prepared by any of the methods well know n in the art.
  • mice were divided into four cohorts and injected with: (i) a vehicle, (ii) MyoAAV-3xFLAG mTNNT2 (mouse Tnnt2 (iii) MyoAAV-3xFLAG mTNNT2 + MyoAAV-scrambled miRNA, (iii) or MyoAAV-3xFLAG-mTNNT2 + MyoAAV- endogenous mTNNT2 miRNA
  • Tissues were harvested from mice two weeks after injection. Incorporation of the mTNNT2 transgene into the sarcomere was quantified by capillary electrophoresis. Endogenous mouse Tnnl2 transcript was quantified by qPCR.
  • FIG. 1 shows an electrophoresis assay of 3xFLAG-TNNT2 transgene protein levels in mouse heart.
  • FIG. 2 shows a graph of 3xFLAG-TNNT2 transgene protein levels in mouse heart.
  • FIG. 3 shows a graph of endogenous mouse Tmt2 mRNA expression in mice. Overexpression of mouse TNNT2 alone or with scrambled miRNA (scrambled knockdown) resulted in 25-36% 3xFLAG-TNNT2 transgene protein incorporation in the sarcomere with no reduction of endogenous TNNT2 expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des cassettes d'expression et des procédés qui réduisent l'expression d'un gène TNNT2 endogène tout en fournissant un transgène TNNT2 non mutant (tTNNT2), ce qui entraîne une incorporation nettement plus importante du transgène TNNT2 dans le sarcomère que lors de l'administration du transgène TNNT2 seul.
PCT/US2025/026015 2024-04-24 2025-04-23 Approche de thérapie génique pour le traitement de troubles associés à tnnt2 Pending WO2025226841A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463638086P 2024-04-24 2024-04-24
US63/638,086 2024-04-24

Publications (1)

Publication Number Publication Date
WO2025226841A1 true WO2025226841A1 (fr) 2025-10-30

Family

ID=95783946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/026015 Pending WO2025226841A1 (fr) 2024-04-24 2025-04-23 Approche de thérapie génique pour le traitement de troubles associés à tnnt2

Country Status (1)

Country Link
WO (1) WO2025226841A1 (fr)

Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017A (en) 1841-03-26 The graphic co
US191079A (en) 1877-05-22 Improvement in nut-locks
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993024641A2 (fr) 1992-06-02 1993-12-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Virus adeno-associe a sequences terminales inversees utilisees comme promoteur
WO2001038187A1 (fr) 1999-11-29 2001-05-31 Kimberly-Clark Worldwide, Inc. Recipient pour articles de nettoyage humides a fermeture amelioree
US20040171156A1 (en) 1995-06-07 2004-09-02 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
WO2005033321A2 (fr) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Variantes des virus associes aux adenovirus (aav), sequences, vecteurs les contenant, et leur utilisation
WO2006110689A2 (fr) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Procede d'augmentation de la fonction d'un vecteur aav
WO2007127264A2 (fr) 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Procédé évolutif de production d'aav
WO2008027084A2 (fr) 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Vecteurs aav modifiés ayant une immunogénicité de capside réduite et utilisation de ceux-ci
WO2009073104A2 (fr) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci
WO2009073103A2 (fr) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-28,27,-29,-32,-33, et -35 de la sous-famille b et utilisations de ceux-ci
WO2009105084A2 (fr) 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Adénovirus c de la sous-famille simiesque sadv-40, -31, et -34 et leurs utilisations
WO2009134681A2 (fr) 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Vecteurs viraux aav7 pour une administration ciblée de cellules rpe
WO2009136977A2 (fr) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2010051367A1 (fr) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
WO2010138675A1 (fr) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Adénovirus simien 41 et ses utilisations
US20110023353A1 (en) 2010-10-07 2011-02-03 Joe Ciciulla Process of making biodiesel
WO2012112832A1 (fr) 2011-02-17 2012-08-23 The Trustees Of The University Of Pennsylvania Compositions et procédés pour modifier une spécificité tissulaire et améliorer le transfert d'un gène induit par aav9
WO2015054653A2 (fr) 2013-10-11 2015-04-16 Massachusetts Eye & Ear Infirmary Méthodes de prédiction de séquences virales ancestrales et leurs utilisations
WO2016179496A1 (fr) 2015-05-07 2016-11-10 Massachusetts Eye And Ear Infirmary Procédés d'administration d'un agent à l'oeil
WO2017019994A2 (fr) 2015-07-30 2017-02-02 Massachusetts Eye And Ear Infirmary Séquences virales ancestrales et leurs utilisations
US9596220B2 (en) 2010-12-16 2017-03-14 Microsoft Technology Licensing, Llc Secure protocol for peer-to-peer network
WO2017100791A1 (fr) 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Matériaux et méthodes permettant d'apporter des acides nucléiques à des cellules cochléaires et vestibulaires
US9719010B2 (en) 2007-05-30 2017-08-01 Baker Hughes Incorporated Use of nano-sized phyllosilicate minerals in viscoelastic surfactant fluids
WO2018209154A1 (fr) 2017-05-10 2018-11-15 Massachusetts Eye And Ear Infirmary Procédés et compositions pour modifier la dépendance à une protéine activant l'assemblage (app) de virus
WO2019067982A2 (fr) 2017-09-29 2019-04-04 Massachusetts Eye And Ear Infirmary Production de virus adéno-associés dans des cellules d'insectes
WO2019195701A1 (fr) 2018-04-05 2019-10-10 Massachusetts Eye And Ear Infirmary Procédés de fabrication et d'utilisation de bibliothèques combinatoires d'acides nucléiques à code-barres ayant une variation définie
WO2019207163A1 (fr) 2018-04-27 2019-10-31 Nabors Lux 2 Sarl Système et procédé pour effectuer des opérations souterraines
WO2019217911A1 (fr) 2018-05-11 2019-11-14 Massachusetts Eye And Ear Infirmary Tropisme hépato-spécifique de virus adéno-associés
US10519198B2 (en) 2013-09-13 2019-12-31 California Institute Of Technology Selective recovery
WO2020041498A1 (fr) 2018-08-21 2020-02-27 Massachusetts Eye And Ear Infirmary Compositions et procédés pour moduler l'efficacité de transduction de virus adéno-associés
WO2020086881A1 (fr) 2018-10-25 2020-04-30 Baxalta Incorporated Système triple plasmide aav
US10786568B2 (en) 2017-02-28 2020-09-29 The Trustees Of The University Of Pennsylvania AAV mediated influenza vaccines
WO2020210839A1 (fr) 2019-04-12 2020-10-15 Massachusetts Eye And Ear Infirmary Procédés et compositions pour améliorer l'assemblage de virus adéno-associés (aav)
WO2020235543A1 (fr) 2019-05-20 2020-11-26 Ｊｃｒファーマ株式会社 Molécule d'acide nucléique utilisée pour la production d'un virion aav recombinant
WO2021050974A1 (fr) 2019-09-12 2021-03-18 The Broad Institute, Inc. Capsides de virus adéno-associés modifiées
WO2021077000A1 (fr) 2019-10-16 2021-04-22 The Broad Institute, Inc. Compositions de ciblage musculaire modifiées
WO2023178339A2 (fr) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Méthodes et compositions pour traiter une cardiomyopathie liée à tnnt2 avec un vecteur viral
WO2023178337A2 (fr) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Méthodes et compositions pour traiter une cardiomyopathie liée à rbm20 avec un vecteur viral
WO2023200742A2 (fr) * 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Capsides pour la thérapie génique à plakophilline-2

Patent Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017A (en) 1841-03-26 The graphic co
US191079A (en) 1877-05-22 Improvement in nut-locks
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993024641A2 (fr) 1992-06-02 1993-12-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Virus adeno-associe a sequences terminales inversees utilisees comme promoteur
US20040171156A1 (en) 1995-06-07 2004-09-02 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
WO2001038187A1 (fr) 1999-11-29 2001-05-31 Kimberly-Clark Worldwide, Inc. Recipient pour articles de nettoyage humides a fermeture amelioree
US20190015527A1 (en) 2003-09-30 2019-01-17 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7906111B2 (en) 2003-09-30 2011-03-15 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US10973928B2 (en) 2003-09-30 2021-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US10265417B2 (en) 2003-09-30 2019-04-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US10485883B2 (en) 2003-09-30 2019-11-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US10722598B2 (en) 2003-09-30 2020-07-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US10695441B2 (en) 2003-09-30 2020-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
US20200155704A1 (en) 2003-09-30 2020-05-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2005033321A2 (fr) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Variantes des virus associes aux adenovirus (aav), sequences, vecteurs les contenant, et leur utilisation
US9737618B2 (en) 2003-09-30 2017-08-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor
US10626415B2 (en) 2005-04-07 2020-04-21 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
US20200208176A1 (en) 2005-04-07 2020-07-02 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
WO2006110689A2 (fr) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Procede d'augmentation de la fonction d'un vecteur aav
US20200325491A1 (en) 2005-04-07 2020-10-15 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US10301648B2 (en) 2005-04-07 2019-05-28 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
US20190218574A1 (en) 2005-04-07 2019-07-18 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US20200385689A1 (en) 2006-04-28 2020-12-10 The Trustees Of The University Of Pennsylvania Scalable production method for aav
WO2007127264A2 (fr) 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Procédé évolutif de production d'aav
WO2008027084A2 (fr) 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Vecteurs aav modifiés ayant une immunogénicité de capside réduite et utilisation de ceux-ci
US20190055523A1 (en) 2006-04-28 2019-02-21 The Trustees Of The University Of Pennsylvania Scalable production method for aav
US10155931B2 (en) 2006-04-28 2018-12-18 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
US20090317417A1 (en) 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
US9719010B2 (en) 2007-05-30 2017-08-01 Baker Hughes Incorporated Use of nano-sized phyllosilicate minerals in viscoelastic surfactant fluids
WO2009105084A2 (fr) 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Adénovirus c de la sous-famille simiesque sadv-40, -31, et -34 et leurs utilisations
US20160051603A1 (en) 2007-11-28 2016-02-25 The Trustees Of The University Of Pennsylvania Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof
US20160244783A1 (en) 2007-11-28 2016-08-25 The Trustees Of The University Of Pennsylvania SIMIAN SUBFAMILY E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38 AND USES THEREOF
US8231880B2 (en) 2007-11-28 2012-07-31 The Trustess Of The University Of Pennsylvania Simian subfamily C adenoviruses SAdV-40, -31, and -34 and uses thereof
WO2009073104A2 (fr) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci
US8524219B2 (en) 2007-11-28 2013-09-03 The Trustees Of The University Of Pennsylvania Simian subfamily B adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and uses thereof
WO2009073103A2 (fr) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-28,27,-29,-32,-33, et -35 de la sous-famille b et utilisations de ceux-ci
US9206238B2 (en) 2007-11-28 2015-12-08 The Trustees Of The University Of Pennsylvania Simian subfamily B adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and uses thereof
US9359618B2 (en) 2007-11-28 2016-06-07 The Trustees Of The University Of Pennsylvania Simian subfamily E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38 and uses thereof
US8685387B2 (en) 2007-11-28 2014-04-01 The Trustees Of The University Of Pennsylvania Simian E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38
US9597363B2 (en) 2008-03-04 2017-03-21 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
US20170183636A1 (en) 2008-03-04 2017-06-29 The Trustees Of The University Of Pennsylvania Simian Adenoviruses SAdV-36, -42.1, -42.2, and -44 and Uses Thereof
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
WO2009136977A2 (fr) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2009134681A2 (fr) 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Vecteurs viraux aav7 pour une administration ciblée de cellules rpe
WO2010051367A1 (fr) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
US10501757B2 (en) 2008-10-31 2019-12-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50, and uses thereof
US9593346B2 (en) 2008-10-31 2017-03-14 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50, and uses thereof
US20200263201A1 (en) 2008-10-31 2020-08-20 The Trustees Of The University Of Pennsylvania Simian Adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50, and Uses Thereof
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
WO2010138675A1 (fr) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Adénovirus simien 41 et ses utilisations
US9617561B2 (en) 2009-05-29 2017-04-11 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
US20110023353A1 (en) 2010-10-07 2011-02-03 Joe Ciciulla Process of making biodiesel
US9596220B2 (en) 2010-12-16 2017-03-14 Microsoft Technology Licensing, Llc Secure protocol for peer-to-peer network
US9884071B2 (en) 2011-02-17 2018-02-06 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
WO2012112832A1 (fr) 2011-02-17 2012-08-23 The Trustees Of The University Of Pennsylvania Compositions et procédés pour modifier une spécificité tissulaire et améliorer le transfert d'un gène induit par aav9
US10406173B2 (en) 2011-02-17 2019-09-10 Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
US20200101099A1 (en) 2011-02-17 2020-04-02 The Trustees Of The University Of Pennsylvania Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer
US10519198B2 (en) 2013-09-13 2019-12-31 California Institute Of Technology Selective recovery
US9695220B2 (en) 2013-10-11 2017-07-04 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
WO2015054653A2 (fr) 2013-10-11 2015-04-16 Massachusetts Eye & Ear Infirmary Méthodes de prédiction de séquences virales ancestrales et leurs utilisations
US20200318082A1 (en) 2013-10-11 2020-10-08 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
US9719070B2 (en) 2013-10-11 2017-08-01 Massachusetts Eye And Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
US10526584B2 (en) 2013-10-11 2020-01-07 The Schepens Eye Research Institute, Inc. Methods of predicting ancestral virus sequences and uses thereof
US10119125B2 (en) 2013-10-11 2018-11-06 Massachusetts Eye And Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
US20200123504A1 (en) 2013-10-11 2020-04-23 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
US10881548B2 (en) 2015-05-07 2021-01-05 Massachusetts Eye And Ear Infirmary Methods of delivering an agent to the eye
WO2016179496A1 (fr) 2015-05-07 2016-11-10 Massachusetts Eye And Ear Infirmary Procédés d'administration d'un agent à l'oeil
WO2017019994A2 (fr) 2015-07-30 2017-02-02 Massachusetts Eye And Ear Infirmary Séquences virales ancestrales et leurs utilisations
US10738087B2 (en) 2015-07-30 2020-08-11 Massachusetts Eye And Ear Infirmary Ancestral virus sequences and uses thereof
WO2017100791A1 (fr) 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Matériaux et méthodes permettant d'apporter des acides nucléiques à des cellules cochléaires et vestibulaires
US20180369414A1 (en) 2015-12-11 2018-12-27 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
US10786568B2 (en) 2017-02-28 2020-09-29 The Trustees Of The University Of Pennsylvania AAV mediated influenza vaccines
US20190330278A1 (en) 2017-05-10 2019-10-31 Massachusetts Eye And Ear Infirmary Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
WO2018209154A1 (fr) 2017-05-10 2018-11-15 Massachusetts Eye And Ear Infirmary Procédés et compositions pour modifier la dépendance à une protéine activant l'assemblage (app) de virus
US20200231986A1 (en) 2017-09-29 2020-07-23 Massachusetts Eye And Ear Infirmary Production of adeno-associated viruses in insect cells
WO2019067982A2 (fr) 2017-09-29 2019-04-04 Massachusetts Eye And Ear Infirmary Production de virus adéno-associés dans des cellules d'insectes
WO2019195701A1 (fr) 2018-04-05 2019-10-10 Massachusetts Eye And Ear Infirmary Procédés de fabrication et d'utilisation de bibliothèques combinatoires d'acides nucléiques à code-barres ayant une variation définie
WO2019207163A1 (fr) 2018-04-27 2019-10-31 Nabors Lux 2 Sarl Système et procédé pour effectuer des opérations souterraines
WO2019217911A1 (fr) 2018-05-11 2019-11-14 Massachusetts Eye And Ear Infirmary Tropisme hépato-spécifique de virus adéno-associés
WO2020041498A1 (fr) 2018-08-21 2020-02-27 Massachusetts Eye And Ear Infirmary Compositions et procédés pour moduler l'efficacité de transduction de virus adéno-associés
WO2020086881A1 (fr) 2018-10-25 2020-04-30 Baxalta Incorporated Système triple plasmide aav
WO2020210839A1 (fr) 2019-04-12 2020-10-15 Massachusetts Eye And Ear Infirmary Procédés et compositions pour améliorer l'assemblage de virus adéno-associés (aav)
WO2020235543A1 (fr) 2019-05-20 2020-11-26 Ｊｃｒファーマ株式会社 Molécule d'acide nucléique utilisée pour la production d'un virion aav recombinant
WO2021050974A1 (fr) 2019-09-12 2021-03-18 The Broad Institute, Inc. Capsides de virus adéno-associés modifiées
WO2021077000A1 (fr) 2019-10-16 2021-04-22 The Broad Institute, Inc. Compositions de ciblage musculaire modifiées
WO2023178339A2 (fr) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Méthodes et compositions pour traiter une cardiomyopathie liée à tnnt2 avec un vecteur viral
WO2023178337A2 (fr) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Méthodes et compositions pour traiter une cardiomyopathie liée à rbm20 avec un vecteur viral
WO2023200742A2 (fr) * 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Capsides pour la thérapie génique à plakophilline-2

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical dosage form tablets", 1989, MARCEL DEKKER, INC.
"Remington - The science and practice of pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
ANSEL ET AL.: "Pharmaceutical dosage forms and drug delivery systems", 1995, WILLIAMS AND WILKINS
DIMATTIA ET AL., J. VIROL., vol. 86, no. 12, 2012, pages 6947 - 6958
HERMONATMUZYCZKA, PNAS, vol. 81, 1984, pages 6466 - 6470
KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801
MUZYCZKA, J. CLIN. INVEST., vol. 94, 1994, pages 1351
RAUPP ET AL., J. VIROL., vol. 81, no. 22, 2007, pages 12260 - 408
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 03822 - 3828
SRIVASTAVA, CURR. OPIN. VIROL., vol. 21, 2017, pages 75 - 80
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072 - 2081
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251 - 3260
WEST ET AL., VIROLOGY, vol. 160, 1987, pages 38 - 47
WU ET AL., J. VIROL., vol. 80, no. 22, 2006, pages 11393 - 7

Similar Documents

Publication Publication Date Title
AU2020217441B2 (en) Recombinant Adeno-Associated Virus Delivery Of Exon 2-Targeted U7snRNA Polynucleotide Constructs
US20230242910A1 (en) Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing
Chamberlain et al. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids
CN109069672B (zh) 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症
KR102527259B1 (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
JP2016525356A (ja) 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
JP2025139591A (ja) ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法
US12371710B2 (en) Modified AAV constructs and uses thereof
JP2019515663A (ja) 組織特異的発現のための改変ｕ６プロモーターシステム
JP2024032967A (ja) ジスフェリン二重ベクターを用いた遺伝子治療
US20240335565A1 (en) Junctophilin-2 (jph2) gene therapy using aav vector
EP4504952A1 (fr) Compositions et méthodes pour troubles musculaires
WO2025226841A1 (fr) Approche de thérapie génique pour le traitement de troubles associés à tnnt2
CN119630687A (zh) 用于治疗xlmtm的组合物
WO2025071848A1 (fr) Capsides à déciblage du foie
WO2024220722A1 (fr) Compositions et procédés pour expression spécifique de tissu de thérapies géniques
CN120787264A (zh) 肝脏去靶向衣壳
Flotte Adeno-associated virus-mediated gene transfer for lung diseases
WO2025226842A1 (fr) Contrôle d'expression par des arnmi exprimés par drg
WO2023081683A1 (fr) Thérapie génique pour syndrome de prader-willi
US20250276095A1 (en) Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025015036A1 (fr) Approche de thérapie génique par vaa pour le traitement de la lgmd2b/dysferlinopathie
WO2025081023A1 (fr) Compositions et méthodes pour traiter des troubles musculaires
US20230174976A1 (en) Targeted rna editing using engineered adenosine deaminase acting on trna (adat) systems
WO2024050064A1 (fr) Capside d'aav hybride et ses utilisations